• Mainstream genetic testing for high-grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience.
    • Srinivasa S, Bowman M, Titterton L, Harnett P, Brand A, Kirk J, Ragunathan A.
    • Aust N Z J Obstet Gynaecol. 2023 Feb 13. doi: 10.1111/ajo.13650. Epub ahead of print.
    • Measuring high-risk parents' opinions about direct-to-consumer genetic testing for adult-onset inherited cancer syndromes in their adolescent and young adult children.
    • Hasser E, Peshkin BN, Hamilton JG, Brower J, Ovadia H, Friedman Ross L, Sacca R, Tarini B, Domchek SM, Vittone S, Sleiman M Jr, Isaacs C, Knerr S, Wilfond BS, Tercyak KP.
    • J Genet Couns. 2023 Feb 7. doi: 10.1002/jgc4.1685. Epub ahead of print.
    • Disparities in the uptake of cascade genetic testing among family members of mutation-positive lynch and HBOC syndrome patients. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Namey E, Dudley B, Horton C, Carraway C, Zhou J, Hatton W, Komala T, Milliard C, Namey T, Karloski E, Brand R.
    • Fam Cancer. [O-05: Research Categories» Lynch syndrome.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Actionable pathogenic germline variants discovered by panel-based hereditary cancer testing in families with previously identified pathogenic variants. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Neumann C, Mcsweeny M, Rainey K, Campbell H, Nguyen C, Hall M.
    • Fam Cancer. [P-13: Research Categories » Counseling, Behavioral Health, Psychosocial, and Survivorship.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Innovative approaches to expanding cancer genetic testing in Michigan (project might). [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Stoffel EM, Austin S, Koeppe E, Hanson EN, Delacroix E, Rizzo E, Griggs JJ, Resnicow K.
    • Fam Cancer. [P-17: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Attitudes about sharing genetic test results in families with hereditary cancer syndromes. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Guivatchian E, Koeppe E, Stoffel EM.
    • Fam Cancer. [P-22: Research Categories » Other.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Pairing tumor testing with germline sequencing increases the number of pathogenic germline variants identified. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Nefeli Dimopoulos C, Brierly K, Gibson J, Walther Z, Llor X.
    • Fam Cancer. [P-32: Research Categories» Gastric cancer-related syndromes.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Parent-of-origin detection and chromosome-scale haplotyping using long-read DNA methylation sequencing and Strand-seq.
    • Akbari V, Hanlon VCT, O’Neill K, Lefebvre L, Schrader KA, Lansdorp PM, Jones SJM.
    • Cell Genom. 2022 Dec 21. doi: 10.1016/j.xgen.2022.100233. Epub ahead of print.

    •• Research news: Genetic Test Identifies Parental Source of Cancer Variant. (Medscape Oncology)

    • Informational needs of individuals from BRCA-harboring families: a systematic review and content analysis.
    • Park SY, Kim Y, Kim S, Katapodi MC.
    • Genet Med. 2022 Dec 18:S1098-3600(22)01068-1. doi: 10.1016/j.gim.2022.100001. Epub ahead of print.
    • Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
    • Michaelson-Cohen R, Cohen MJ, Cohen C, Greenberg D, Shmueli A, Lieberman S, Tomer A, Levy-Lahad E, Lahad A.
    • Cancers (Basel). 2022 Dec 12;14(24):6113. doi: 10.3390/cancers14246113.
    • Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
    • Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K.
    • J Hum Genet. 2022 Dec 8. doi: 10.1038/s10038-022-01097-y. Epub ahead of print.
    • Yes, We Can, But Should We? Ethical Considerations in Reporting Germline Findings From Paired Tumor-Normal Genomic Testing in Patients With Advanced Cancer.
    • Hunter CL, Helft PR.
    • J Clin Oncol. 2022 Dec 5:JCO2200796. doi: 10.1200/JCO.22.00796. Epub ahead of print.
    • BRCAShare-Assessment of an animated digital message for intrafamilial communication of pathogenic variant positive test results: A feasibility study.
    • Aeilts AM, Carpenter KM, Hovick SR, Byrne L, Shoben AB, Senter L.
    • J Genet Couns. 2022 Nov 25. doi: 10.1002/jgc4.1656. Epub ahead of print.
    • Fatalism and metaphor in Confucianism: A qualitative study of barriers to genetic testing among first-degree relatives of hereditary cancer patients from China.
    • Jiang C, Liu L, Wang Y, Wu L, Zhang W, Wu X.
    • Psychooncology. 2022 Nov 15. doi: 10.1002/pon.6068. Epub ahead of print.
    • Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer.
    • Hollasch M, Antonarakis ES.
    • OncLive. 2022 Nov 11.
    • Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing.
    • Rosa K, Antonarakis ES.
    • OncLive. 2022 Nov 11.
    • Dr. Shore on the Importance of Genetic Testing in Prostate Cancer.
    • Shore N.
    • OncLive. OncLive TV. 2022 Nov 11.
    • BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance.
    • Scott R, Rimel BJ.
    • OncLive. 2022 Nov 3.
    • Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants.
    • Liu YL, Maio A, Kemel Y, Salo-Mullen EE, Sheehan M, Tejada PR, Trottier M, Arnold AG, Fleischut MH, Latham A, Carlo MI, Murciano-Goroff YR, Walsh MF, Mandelker D, Mehta N, Bandlamudi C, Arora K, Zehir A, Berger MF, Solit DB, Aghajanian C, Diaz LA Jr, Robson ME, Brown CL, Offit K, Hamilton JG, Stadler ZK.
    • Cancer. 2022 Nov 1;128(21):3870-3879. doi: 10.1002/cncr.34434. Epub 2022 Aug 30.
    • Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
    • Negri S, De Ponti E, Sina FP, Sala E, Dell'Oro C, Roversi G, Lazzarin S, Delle Marchette M, Inzoli A, Toso C, Fumagalli S, Campanella M, Kotsopoulos J, Fruscio R.
    • Mol Genet Genomic Med. 2022 Oct 28:e2071. doi: 10.1002/mgg3.2071. Epub ahead of print.
    • What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.
    • Frey MK, Ahsan MD, Badiner N, Lin J, Narayan P, Nitecki R, Rauh-Hain JA, Moss H, Fowlkes RK, Thomas C, Bergeron H, Christos P, Levi SR, Blank SV, Holcomb K, Cantillo E, Sharaf RN, Lipkin S, Offit K, Chapman-Davis E.
    • Cancer. 2022 Oct 27. doi: 10.1002/cncr.34482. Epub ahead of print.
    • Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
    • O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
    • Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.
    • Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort.
    • Sarki M, Ming C, Aceti M, Fink G, Aissaoui S, Bürki N, Graffeo R, Heinimann K, Zufferey MC, Monnerat C, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC.
    • J Pers Med. 2022 Oct 19;12(10):1740. doi: 10.3390/jpm12101740.
    • Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review.
    • Young AL, Imran A, Spoelma MJ, Williams R, Tucker KM, Halliday J, Forrest LE, Wakefield CE, Butow PN.
    • Eur J Hum Genet. 2022 Oct 17. doi: 10.1038/s41431-022-01200-z. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Missed Variant Update Delays Li-Fraumeni Diagnosis.
    • Ray T.
    • Precision Oncology News. 2022 Oct 12.

    Special article:

    Is there a duty to reinterpret genetic data? The ethical dimensions.

    • Study: Teens and young adults respond well to learning about familial cancer risk
    • [No author given]
    • FORCE. XRAY. 2022 Oct 11.

    Original research:

    Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.

    Commentary:

    Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

    • Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
    • Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, Lipkin S, Frey MK.
    • Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. Epub ahead of print.
    • Use of a chatbot to increase uptake of cascade genetic testing.
    • Schmidlen T, Jones CL, Campbell-Salome G, McCormick CZ, Vanenkevort E, Sturm AC.
    • J Genet Couns. 2022 Oct;31(5):1219-1230. doi: 10.1002/jgc4.1592. Epub 2022 May 26.
    • Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment.
    • Nehoray B, Slavin TP, Sun CL, Hurley K, King E, Tsang KK, Cervantes A, Mokhnatkin JV, Sand S, Mejia R, Reb A, Samimi G, Gray S, Blazer KR, Weitzel JN.
    • J Genet Couns. 2022 Oct;31(5):1164-1172. doi: 10.1002/jgc4.1587. Epub 2022 May 26.
    • Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    • Ohneda K, Hamanaka Y, Kawame H, Fuse N, Nagami F, Suzuki Y, Yamaguchi-Kabata Y, Shimada M, Masamune A, Aoki Y, Ishida T, Yamamoto M.
    • Breast Cancer. 2022 Sep 26. doi: 10.1007/s12282-022-01404-7. Epub ahead of print.
    • Fanconi Anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthood.
    • Maxwell KN, Patel V, Nead KT, Merrill S, Clark D, Jiang Q, Wubbenhorst B, D'Andrea K, Cohen RB, Domchek SM, Morrissette JJD, Greenberg RA, Babushok DV, Nathanson KL.
    • Clin Genet. 2022 Sep 12. doi: 10.1111/cge.14231. Epub ahead of print.
    • Case report
    • Nijmegen Breakage Syndrome.
    • Varon R, Demuth I, Chrzanowska KH.
    • 1999 May 17 [updated 2022 Aug 18]. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors.
    • I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.
    • Wilfond BS.
    • J Pediatr. 2022 Aug 16:S0022-3476(22)00728-4. doi: 10.1016/j.jpeds.2022.08.019. Epub ahead of print.
    • Commentary

    Original research:

    Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.

    • Environmental scan of family chart linking for genetic cascade screening in a U.S. integrated health system.
    • Haas CB, Ralston J, Fullerton SM, Scrol A, Henrikson NB.
    • Front Genet. 2022 Aug 11;13:886650. doi: 10.3389/fgene.2022.886650.
    • Feasibility, acceptability, and limited efficacy of health system-led familial risk notification: protocol for a mixed-methods evaluation.
    • Blasi PR, Scrol A, Anderson ML, Gray MF, Tiffany B, Fullerton SM, Ralston JD, Leppig KA, Henrikson NB.
    • Pilot Feasibility Stud. 2022 Aug 9;8(1):174. doi: 10.1186/s40814-022-01142-9.
    • Impact of BRCA1/2 cascade testing on anxiety, depression, and cancer worry levels among unaffected relatives in a multiethnic Asian cohort.
    • Padmanabhan H, Mariapun S, Lee SY, Hassan NT, Lee DS, Meiser B, Wong SW, Lee YQ, Yip CH, Teo SH, Thong MK, Taib NAM, Yoon SY.
    • J Genet Couns. 2022 Aug 1. doi: 10.1002/jgc4.1619. Epub ahead of print.
    • Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants.
    • Shah I, Silva-Santisteban A, Germansky KA, Kandasamy C, Mlabasati J, Huang DC, Wadhwa V, Bilal M, Sawhney MS.
    • Pancreas. 2022 Aug 1;51(7):733-738. doi: 10.1097/MPA.0000000000002104.
    • Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.
    • McDonnell GA, Peshkin BN, DeMarco TA, Peterson SK, Arun BK, Miesfeldt S, O'Neill SC, Schneider K, Garber J, Isaacs C, Luta G, Tercyak KP.
    • Pediatrics. 2022 Aug 1;150(2):e2022056339. doi: 10.1542/peds.2022-056339.

    Commentary:

    Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.

    Research news: Study: Teens and young adults respond well to learning about familial cancer risk. (FORCE. XRAYS)

    • Liquid Biopsy Revealed HBOC Pedigree and Led to Medical Management Among the Relatives.
    • Ogawa C, Hirasawa A, Sogawa R, Hasuoka K, Tomida S, Futagawa M, Urakawa Y, Kochi M, Yamamoto H, Nakamura K, Masuyama H.
    • Acta Med Okayama. 2022 Aug;76(4):479-483. doi: 10.18926/AMO/63908.
    • Germline genetics of prostate cancer.
    • Khan HM, Cheng HH.
    • Prostate. 2022 Aug;82 Suppl 1:S3-S12. doi: 10.1002/pros.24340.
    • Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting.
    • Everett JN, Dettwyler SA, Jing X, Stender C, Schmitter M, Baptiste A, Chun J, Kawaler EA, Khanna LG, Gross SA, Gonda TA, Beri N, Oberstein PE, Simeone DM.
    • Cancer Med. 2022 Jul 30. doi: 10.1002/cam4.5059. Epub ahead of print.
    • The Communication Chain of Genetic Risk: Analyses of Narrative Data Exploring Proband–Provider and Proband–Family Communication in Hereditary Breast and Ovarian Cancer.
    • Pedrazzani C, Aceti M, Schweighoffer R, Kaiser-Grolimund A, Bürki N, Chappuis PO, Graffeo R, Monnerat C, Pagani O, Rabaglio M, Katapodi MC, Caiata-Zufferey M.
    • J Pers Med. 2022 Jul 29;12(8):1249. doi: 10.3390/jpm12081249.
    • A qualitative study of unaffected ATM and CHEK2 carriers: How participants make meaning of 'moderate risk' genetic results in a population breast cancer screening trial.
    • James JE, Riddle L, Caruncho M, Koenig BA, Joseph G.
    • J Genet Couns. 2022 Jul 25. doi: 10.1002/jgc4.1617. Epub ahead of print.
    • Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.
    • Leader AE, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri VN.
    • J Community Genet. 2022 Jul 22. doi: 10.1007/s12687-022-00603-1. Epub ahead of print.
    • Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.
    • Mukherjee S, Bandlamudi C, Hellmann MD, Kemel Y, Drill E, Rizvi H, Tkachuk K, Khurram A, Walsh MF, Zauderer MG, Mandelker D, Topka S, Zehir A, Srinivasan P, Esai Selvan M, Carlo MI, Cadoo KA, Latham A, Hamilton JG, Liu YL, Lipkin SM, Belhadj S, Bond GL, Gümüs ZH, Klein RJ, Ladanyi M, Solit DB, Robson ME, Jones DR, Kris MG, Vijai J, Stadler ZK, Amos CI, Taylor BS, Berger MF, Rudin CM, Offit K.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1450-1459. doi: 10.1158/1055-9965.EPI-21-1287.
    • Genetic testing in prostate cancer management: Considerations informing primary care.
    • Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin ME.
    • CA Cancer J Clin. 2022 Jul;72(4):360-371. doi: 10.3322/caac.21720. Epub 2022 Feb 24.
    • Identification of women at risk of hereditary breast-ovarian cancer among participants in a population-based breast cancer screening.
    • Bonelli L, Valle I, Rebora I, Ricci P, Biocchi L, Bruschi G, Parodi S, Bruzzone C, Varesco L.
    • Fam Cancer. 2022 Jul;21(3):309-318. doi: 10.1007/s10689-021-00281-x. Epub 2021 Oct 20.
    • Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program.
    • Braley EF, Bedard AC, Nuk J, Hong Q, Bedard JEJ, Sun S, Schrader KA.
    • Fam Cancer. 2022 Jul;21(3):369-374. doi: 10.1007/s10689-021-00270-0. Epub 2021 Jul 7.
    • Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
    • Ossa Gomez CA, Achatz MI, Hurtado M, Sanabria-Salas MC, Sullcahuaman Y, Chávarri-Guerra Y, Dutil J, Nielsen SM, Esplin ED, Michalski ST, Bristow SL, Hatchell KE, Nussbaum RL, Pineda-Alvarez DE, Ashton-Prolla P.
    • JCO Glob Oncol. 2022 Jul;8:e2200104. doi: 10.1200/GO.22.00104.
    • Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
    • Casolino R, Corbo V, Beer P, Hwang CI, Paiella S, Silvestri V, Ottini L, Biankin AV.
    • Cancers (Basel). 2022 Jun 30;14(13):3239. doi: 10.3390/cancers14133239.
    • Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk.
    • Jennings C, Wynn J, Miguel C, Levinson E, Florido ME, White M, Sands CB, Schwartz LA, Daly M, O'Toole K, Buys SS, Glendon G, Hanna D, Andrulis IL, Terry MB, Chung WK, Bradbury A.
    • J Pediatr. 2022 Jun 28:S0022-3476(22)00601-1. doi: 10.1016/j.jpeds.2022.06.027. Epub ahead of print.

    Commentary:

    I know things now: The challenges for genetic counseling of adolescents with a family history of hereditary breast cancer.

    • TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    • Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K; Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study and the TRACEBACK Study.
    • J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9.
    • Healthcare Predictors of Information Dissemination About Genetic Risks.
    • Henderson V, Strayhorn SM, Bergeron NQ, Strahan DC, Ganschow PS, Khanna AS, Watson K, Hoskins K, Molina Y.
    • Cancer Control. 2022 Jan-Dec [First Published 2022 Jun 6];29:10732748221104666. doi: 10.1177/10732748221104666.
    • Interventions to improve delivery of cancer genetics services in the United States: A scoping review.
    • Bednar EM, Nitecki R, Krause KJ, Rauh-Hain JA.
    • Genet Med. 2022 Jun;24(6):1176-1186. doi: 10.1016/j.gim.2022.03.002. Epub 2022 Apr 7.
    • Review
    • Perceptions and care Recommendations from Previvors: Qualitative analysis of female BRCA1/2 mutation Carriers' experience with genetic testing and counseling.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 May 2 [eCollection 2022 Jun];41:100989. doi: 10.1016/j.gore.2022.100989.
    • Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
    • Azzollini J, Vingiani A, Agnelli L, Tamborini E, Perrone F, Conca E, Capone I, Busico A, Peissel B, Rosina E, Ducceschi M, Mantiero M, Lopez S, Raspagliesi F, Niger M, Duca M, Damian S, Proto C, de Braud F, Pruneri G, Manoukian S.
    • Front Oncol. 2022 Apr 8;12:857515. doi: 10.3389/fonc.2022.857515.
    • A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    • Petrocchi S, Ongaro G, Calvello M, Feroce I, Bonanni B, Pravettoni G.
    • PLoS One. 2022 Apr 8;17(4):e0266327. doi: 10.1371/journal.pone.0266327.

    Identifier: NCT04683068: Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing (BRCA-MEN). (ClinicalTrials.gov)

    • Psychological Determinants of Men's Adherence to Cascade Screening for BRCA1/2.
    • Ongaro G, Petrocchi S, Calvello M, Bonanni B, Feroce I, Pravettoni G.
    • Curr Oncol. 2022 Apr 2;29(4):2490-2503. doi: 10.3390/curroncol29040203.
    • Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing.
    • Frey MK, Finch A, Kulkarni A, Akbari MR, Chapman-Davis E.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12. doi: 10.1200/EDBK_350292.
    • 30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes.
    • Woodward ER, Green K, Burghel GJ, Bulman M, Clancy T, Lalloo F, Schlecht H, Wallace AJ, Evans DG.
    • Eur J Hum Genet. 2022 Apr;30(4):413-419. doi: 10.1038/s41431-021-01011-8. Epub 2021 Dec 6.
    • Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.
    • Sarki M, Ming C, Aissaoui S, Bürki N, Caiata-Zufferey M, Erlanger TE, Graffeo-Galbiati R, Heinimann K, Heinzelmann-Schwarz V, Monnerat C, Probst-Hensch N, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC, On Behalf Of The Cascade Consortium.
    • Cancers (Basel). 2022 Mar 23;14(7):1636. doi: 10.3390/cancers14071636.
    • Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    • Weinmann S, Phillips S, Sweet K, Cosgrove CM, Senter L.
    • Gynecol Oncol. 2022 Mar;164(3):615-621. doi: 10.1016/j.ygyno.2021.12.027. Epub 2022 Jan 5.
    • Residential Locale Is Associated with Disparities in Genetic Testing-Related Outcomes Among BRCA1/2-Positive Women.
    • Dibble KE, Connor AE.
    • J Racial Ethn Health Disparities. 2022 Feb 17. doi: 10.1007/s40615-022-01259-w. Epub ahead of print.
    • Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.
    • Lee J, Ham JY, Park HY, Jung JH, Kim WW, Kang B, Chae YS, Lee SJ, Lee IH, Lee NY.
    • Sci Rep. 2022 Feb 3;12(1):1842. doi: 10.1038/s41598-022-05931-3.
    • Should all patients undergoing genetic testing for hereditary breast cancer syndromes be offered a multigene panel?
    • Silver EL, Niell-Swiller M.
    • Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):36-40. doi: 10.1097/GCO.0000000000000764.
    • Review
    • ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?
    • Mittal A, Pramanik R.
    • Ann Surg Oncol. 2022 Feb;29(2):1433-1434. doi: 10.1245/s10434-021-10880-8. Epub 2021 Oct 15.
    • Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants.
    • Douglas MP, Lin GA, Trosman JR, Phillips KA.
    • J Community Genet. 2022 Feb;13(1):75-80. doi: 10.1007/s12687-021-00563-y. Epub 2021 Nov 6.
    • BRCA1/2 Mutations in Vietnamese Patients with Hereditary Breast and Ovarian Cancer Syndrome.
    • Le TN, Tran VK, Nguyen TT, Vo NS, Hoang TH, Vo HL, Nguyen TT, Nguyen PD, Nguyen VT, Ta TV, Tran HT.
    • Genes (Basel). 2022 Jan 29;13(2):268. doi: 10.3390/genes13020268.
    • Tennis Star Chris Evert Teaches Us That Genetic Testing Is A Lifetime Match.
    • Matloff E.
    • Forbes. Healthcare. 2022 Jan 17.

    News: Tennis Star Chris Evert Teaches Us That Genetic Testing Is a Lifetime Match. (My Gene Counsel)

    • Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    • Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha AC.
    • Cancer. 2022 Jan 1;128(1):94-102. doi: 10.1002/cncr.33866. Epub 2021 Aug 23.

    Editorial:

    Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?

    • Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients.
    • Tsaousis GN, Papadopoulou E, Agiannitopoulos K, Pepe G, Tsoulos N, Boukovinas I, Floros T, Iosifidou R, Katopodi O, Koumarianou A, Markopoulos C, Papazisis K, Venizelos V, Kapsimalis A, Xepapadakis G, Psyrri A, Banu E, Eniu DT, Blidaru A, Stanculeanu DL, Ungureanu A, Ozmen V, Tansan S, Tekinel M, Yalcin S, Nasioulas G.
    • Cancer Genomics Proteomics. 2022 Jan-Feb;19(1):60-78. doi: 10.21873/cgp.20304.
    • Genetic Testing Challenges in Oncology: No Follow-up on Insurer Denial Delays Cancer Risk Management.
    • Ray T.
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 Nov 29.
    • Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol.
    • Kauffman TL, Prado YK, Reyes AA, Zepp JM, Sawyer J, White LL, Martucci J, Salas SB, Vertrees S, Rope AF, Weinmann S, Henrikson NB, Lee SS, Feigelson HS, Hunter JE.
    • J Pers Med. 2021 Nov 13;11(11):1194. doi: 10.3390/jpm11111194.
    • A Focus Group Study of Perceptions of Genetic Risk Disclosure in Members of the Public in Sweden: "I'll Phone the Five Closest Ones, but What Happens to the Other Ten?".
    • Hawranek C, Hajdarevic S, Rosén A.
    • J Pers Med. 2021 Nov 12;11(11):1191. doi: 10.3390/jpm11111191.
    • Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.
    • Combrink HM, Oosthuizen J, Visser B, Chabilal N, Buccimazza I, Foulkes WD, van der Merwe NC.
    • Cancer Genet. 2021 Nov;258-259:1-6. doi: 10.1016/j.cancergen.2021.06.002. Epub 2021 Jun 15.

    Dataset description:

    A South African Indian population group dataset for breast cancer and BRCA1/2 variants.

    • When cascade testing for familial variant seems inadequate to provide clinically actionable information for blood relatives.
    • Apostolou P, Fostira F, Fountzilas G, Razis E, Yannoukakos D, Konstantopoulou I.
    • Cancer Genet. 2021 Nov;258-259:49-50. doi: 10.1016/j.cancergen.2021.08.003. Epub 2021 Aug 24.
    • Case report
    • Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
    • Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S.
    • Cancer Prev Res (Phila). 2021 Nov;14(11):1021-1032. doi: 10.1158/1940-6207.CAPR-20-0642. Epub 2021 Oct 8.
    • Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention.
    • Whitaker KD, Obeid E, Daly MB, Hall MJ.
    • JCO Precis Oncol. 2021 Nov;5:1387-1396. doi: 10.1200/PO.21.00163.
    • Genetic Testing Challenges in Oncology: Same Multigene Cancer Risk Panel Not Right for All.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Oct 28.
    • MSK Fellows Develop Online Resource to Increase Awareness of Genetic Cascade Testing.
    • Kanski A.
    • Precision Oncology News. Technology. 2021 Oct 21.
    • News
    • Experience and Perceptions of a Family Health History Risk Assessment Tool among Multi-Ethnic Asian Breast Cancer Patients.
    • Yoon S, Goh H, Fung SM, Tang S, Matchar D, Ginsburg GS, Orlando LA, Ngeow J, Wu RR.
    • J Pers Med. 2021 Oct 19;11(10):1046. doi: 10.3390/jpm11101046.
    • Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design.
    • Blomen CL, Pott A, Volk AE, Budäus L, Witzel I.
    • Sci Rep. 2021 Oct 11;11(1):20178. doi: 10.1038/s41598-021-98737-8.
    • Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
    • Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.
    • J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.
    • Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center.
    • Mittal A, Deo SVS, Gogia A, Batra A, Kumar A, Bhoriwal S, Deb KS, Dhamija E, Thulkar S, Ramprasad VL, Olopade O, Pramanik R.
    • Ann Surg Oncol. 2021 Oct 2:1–10. doi: 10.1245/s10434-021-10870-w. Epub ahead of print.
    • Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    • Makhnoon S, Tran G, Levin B, Mattie KD, Dreyer B, Volk RJ, Grana G, Arun BK, Peterson SK.
    • Cancer. 2021 Oct 1;127(19):3605-3613. doi: 10.1002/cncr.33668. Epub 2021 Jun 22.
    • Coping response and family communication of cancer risk in men harboring a BRCA mutation: A mixed methods study.
    • Dwyer AA, Hesse-Biber S, Shea H, Zeng Z, Yi S.
    • Psychooncology. 2021 Sep 28. doi: 10.1002/pon.5831. Epub ahead of print.
    • Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report.
    • O'Neill SC, Hamilton JG, Conley CC, Peshkin BN, Sacca R, McDonnell GA, Isaacs C, Robson ME, Tercyak KP.
    • Hered Cancer Clin Pract. 2021 Sep 26;19(1):40. doi: 10.1186/s13053-021-00198-7.
    • Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.
    • Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G.
    • J Med Genet. 2021 Sep 23:jmedgenet-2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print.
    • Case report: Antenatal diagnostic of a polymalformative syndrome due to biallelic BRCA2 mutations.
    • Anquetil A, Khung Savatovsky S, Gavard L, Bazin A, Guimiot F, Dubourg C, Mandelbrot L, Picone O.
    • Clin Case Rep. 2021 Sep 22;9(9):e04838. doi: 10.1002/ccr3.4838.
    • A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk-reducing surgery for hereditary breast and ovarian cancer.
    • Hirayama T, Inayama Y, Odajima S, Yamanaka A, Sekine M, Terao Y, Koide K, Kuwabara Y, Yahata H, Yanaihara N, Nagase S, Kobayashi Y, Sekizawa A.
    • J Obstet Gynaecol Res. 2021 Aug 1. doi: 10.1111/jog.14952. Epub ahead of print.
    • Conference news
    • Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives.
    • Ficarazzi F, Vecchi M, Ferrari M, Pierotti MA.
    • Breast. 2021 Aug;58:121-129. doi: 10.1016/j.breast.2021.04.011. Epub 2021 May 12.
    • Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    • Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, Bergeron H, Chapman-Davis E, Cantillo E, Holcomb K, Blank SV, Liu Y, Thomas C, Christos PJ, Wright DN, Lipkin S, Offit K, Frey MK.
    • Gynecol Oncol. 2021 Aug;162(2):506-516. doi: 10.1016/j.ygyno.2021.05.011. Epub 2021 May 19.
    • TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.
    • Lesueur F, Eon-Marchais S, Bonnet-Boissinot S, Beauvallet J, Dondon MG, Golmard L, Rouleau E, Garrec C, Martinez M, Toulas C, Nguyen TD, Brayotel F, Crivelli L, Maugard CM, Bubien V, Sevenet N, Gesta P, Chieze-Valero S, Nambot S, Goussot V, Mari V, Popovici C, Prieur F, Morin-Meschin ME, Tinat J, Lortholary A, Dreyfus H, Bidart M, Collonge-Rame MA, Mozelle-Nivoix M, Gladieff L, Giraud S, Boutry-Kryza N, Chiesa J, Denizeau P, Bignon YJ, Uhrhammer N, Cohen-Haguenauer O, Vilquin P, Mailliez A, Coupier I, Rey JM, Lacaze E, Béra O, Colas C, Coulet F, Delnatte C, Houdayer C, Lasset C, Lemonnier J, Longy M, Noguès C, Stoppa-Lyonnet D, Vaur D, Andrieu N, Caron O.
    • Cancers (Basel). 2021 Jul 21;13(15):3659. doi: 10.3390/cancers13153659.
    • Evaluation and comparison of hereditary Cancer guidelines in the population.
    • Ritchie JB, Bellcross C, Allen CG, Frey L, Morrison H, Schiffman JD, Welch BM.
    • Hered Cancer Clin Pract. 2021 Jul 17;19(1):31. doi: 10.1186/s13053-021-00188-9.
    • Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma.
    • Everett JN, Burgos G, Chun J, Baptiste A, Khanna LG, Oberstein PE, Simeone DM.
    • Cancer. 2021 Jul 1;127(13):2271-2278. doi: 10.1002/cncr.33500. Epub 2021 Mar 15.
    • Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: Opportunity for prompting family communication.
    • Makhnoon S, Smith HS, Bednar EM, Bhatt A, Turner L, Arun B, Volk RJ, Peterson SK.
    • J Community Genet. 2021 Jul;12(3):439-447. doi: 10.1007/s12687-021-00504-9. Epub 2021 Jan 22.
    • Evaluation of two population screening programmes for BRCA1/2 founder mutations in the Australian Jewish community: a protocol paper.
    • Cousens NE, Tiller J, Meiser B, Barlow-Stewart K, Rowley S, Ko YA, Mahale S, Campbell IG, Kaur R, Bankier A, Burnett L, Jacobs C, James PA, Trainer A, Neil S, Delatycki MB, Andrews L.
    • BMJ Open. 2021 Jun 25;11(6):e041186. doi: 10.1136/bmjopen-2020-041186.
    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.
    • Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N.
    • Can Urol Assoc J. 2021 Jun 22. doi: 10.5489/cuaj.7383. Epub ahead of print.
    • Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.
    • Kim S, Aceti M, Baroutsou V, Bürki N, Caiata-Zufferey M, Cattaneo M, Chappuis PO, Ciorba FM, Graffeo-Galbiati R, Heinzelmann-Schwarz V, Jeong J, Jung MM, Kim SW, Kim J, Lim MC, Ming C, Monnerat C, Park HS, Park SH, Pedrazzani CA, Rabaglio M, Ryu JM, Saccilotto R, Wieser S, Zürrer-Härdi U, Katapodi MC.
    • JMIR Res Protoc. 2021 Jun 11;10(6):e26264. doi: 10.2196/26264.
    • Fanconi Anemia.
    • Mehta PA, Ebens C.
    • 2002 Feb 14 [updated 2021 Jun 3]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.
    • The impact of a cascade testing video on recipients' knowledge, cognitive message processing, and affective reactions: A formative evaluation.
    • Aeilts AM, Carpenter KM, Hovick SR, Byrne L, Shoben AB, Senter L.
    • J Genet Couns. 2021 Jun;30(3):656-664. doi: 10.1002/jgc4.1345. Epub 2020 Nov 3.
    • A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.
    • King B, McHugh J, Snape K.
    • Appl Clin Genet. 2021 May 20;14:255-266. doi: 10.2147/TACG.S261737.
    • Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre.
    • Beard C, Monohan K, Cicciarelli L, James PA.
    • Eur J Hum Genet. 2021 May;29(5):872-880. doi: 10.1038/s41431-021-00848-3. Epub 2021 Mar 15.
    • Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.
    • Doan DK, Schmidt KT, Chau CH, Figg WD.
    • Cancers (Basel). 2021 Apr 29;13(9):2154. doi: 10.3390/cancers13092154.
    • Genetic Testing Challenges in Oncology: BRCA1-Positive Patient Told Paternal Cancer Risk Unimportant.
    • Ray T.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Apr 29.
    • The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    • Tone AA, McCuaig JM, Ricker N, Boghosian T, Romagnuolo T, Stickle N, Virtanen C, Zhang T, Kim RH, Ferguson SE, May T, Laframboise S, Armel S, Demsky R, Volenik A, Stuart-McEwan T, Shaw P, Oza A, Kamel-Reid S, Stockley T, Bernardini MQ.
    • Gynecol Oncol. 2021 Apr 13:S0090-8258(21)00321-8. doi: 10.1016/j.ygyno.2021.04.011. Epub ahead of print.
    • Psychosocial factors related to BRCA1/2 disclosures.
    • Timbs M.
    • Nursing. 2021 Apr 1;51(4):58-61. doi: 10.1097/01.NURSE.0000733956.47297.e6.
    • Genetic Variants in Patients With a Family History of Pancreatic Cancer: Impact of Multigene Panel Testing.
    • Zhu H, Welinsky S, Soper ER, Brown KL, Abul-Husn NS, Lucas AL.
    • Pancreas. 2021 Apr 1;50(4):602-606. doi: 10.1097/MPA.0000000000001804.
    • What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?
    • Bowen DJ, Makhnoon S, Shirts BH, Fullerton SM, Larson E, Ralston JD, Leppig K, Crosslin DR, Veenstra D, Jarvik GP.
    • Patient Educ Couns. 2021 Apr;104(4):726-731. doi: 10.1016/j.pec.2021.01.001. Epub 2021 Jan 7.
    • Clinical implementation of an oncology-specific family health history risk assessment tool.
    • Fung SM, Wu RR, Myers RA, Goh J, Ginsburg GS, Matchar D, Orlando LA, Ngeow J.
    • Hered Cancer Clin Pract. 2021 Mar 20;19(1):20. doi: 10.1186/s13053-021-00177-y.
    • Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and Impact on patients.
    • Nambot S, Bertolone G, Sawka C, Cosset E, Goussot V, Derangère V, Boidot R, Baurand A, Robert M, Coutant C, Loustalot C, Thauvin-Robinet C, Ghiringhelli F, Lançon A, Populaire C, Damette A, Collonge-Rame MA, Meunier-Beillard N, Lejeune C, Albuisson J, Faivre L.
    • Eur J Med Genet. 2021 Mar 19:104196. doi: 10.1016/j.ejmg.2021.104196. Epub ahead of print.
    • Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.
    • Carlson J.
    • Genet Med. 2021 Mar 19. doi: 10.1038/s41436-020-01094-6. Epub ahead of print.
    • Letter

    Original research:

    Assessing relatives' readiness for hereditary cancer cascade genetic testing.

    • Germline FFPE inherited cancer panel testing in deceased family members: implications for clinical management of unaffected relatives.
    • Bennett S, Alexander E, Fraser H, Bowers N, Wallace A, Woodward ER, Lalloo F, Quinn AM, Huang S, Schlecht H, Evans DG.
    • Eur J Hum Genet. 2021 Mar 2. doi: 10.1038/s41431-021-00817-w. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Forged Genetic Test Report Leads to Incorrect Management.
    • Ray T.
    • Precision Oncology News. Diagnostics. 2021 Mar 1.
    • Interventions Facilitating Family Communication of Genetic Testing Results and Cascade Screening in Hereditary Breast/Ovarian Cancer or Lynch Syndrome: A Systematic Review and Meta-Analysis.
    • Baroutsou V, Underhill-Blazey ML, Appenzeller-Herzog C, Katapodi MC.
    • Cancers (Basel). 2021 Feb 23;13(4):925. doi: 10.3390/cancers13040925.
    • Parent-Child Communication and Reproductive Considerations in Families with Genetic Cancer Predisposition Syndromes: A Systematic Review.
    • Dattilo TM, Lipak KG, Clark OE, Gehred A, Sampson A, Quinn G, Zajo K, Sutter ME, Bowman-Curci M, Gardner M, Gerhardt CA, Nahata L.
    • J Adolesc Young Adult Oncol. 2021 Feb;10(1):15-25. doi: 10.1089/jayao.2020.0084. Epub 2020 Sep 8.
    • Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
    • Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H, Brais LK, Perez K, Wolpin BM, Syngal S, Yurgelun MB.
    • JCO Oncol Pract. 2021 Feb;17(2):e236-e247. doi: 10.1200/OP.20.00678. Epub 2021 Jan 13.
    • Cost-Effectiveness of Targeted Genetic Testing for Breast and Ovarian Cancer: A Systematic Review.
    • Koldehoff A, Danner M, Civello D, Rhiem K, Stock S, Müller D.
    • Value Health. 2021 Feb;24(2):303-312. doi: 10.1016/j.jval.2020.09.016. Epub 2021 Jan 5.
    • Review
    • Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.
    • McAlarnen L, Stearns K, Uyar D.
    • Appl Clin Genet. 2021 Jan 14;14:1-9. doi: 10.2147/TACG.S245021.
    • Facilitated cascade testing (FaCT): a randomized controlled trial.
    • Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK.
    • Int J Gynecol Cancer. 2020 Dec 18:ijgc-2020-002118. doi: 10.1136/ijgc-2020-002118. Epub ahead of print.
    • CanRisk Tool - A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants.
    • Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, Roberts J, Ruston R, Walter FM, Tischkowitz M, Easton DF, Antoniou AC.
    • Cancer Epidemiol Biomarkers Prev. 2020 Dec 17:cebp.1319.2020. doi: 10.1158/1055-9965.EPI-20-1319. Epub ahead of print.
    • Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
    • Lee DS, Meiser B, Mariapun S, Hassan T, Yip CH, Mohd Taib NA, Teo SH, Thong MK, Yoon SY.
    • J Genet Couns. 2020 Nov 27. doi: 10.1002/jgc4.1360. Epub ahead of print.
    • Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
    • Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, Nikopensius T, Esko T, Metspalu A, Padrik P, Tõnisson N.
    • Eur J Hum Genet. 2020 Nov 23. doi: 10.1038/s41431-020-00760-2. Epub ahead of print.
    • Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective.
    • [No author given]
    • Clinical OMICs. Molecular Dx. 2020 Nov 17.

    Original research:

    Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.

    • Family communication of genetic test results among women with inherited breast cancer genes.
    • Cragun D, Weidner A, Tezak A, Clouse K, Pal T.
    • J Genet Couns. 2020 Nov 10. doi: 10.1002/jgc4.1356. Epub ahead of print.
    • BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care.
    • Parente DJ.
    • J Am Board Fam Med. 2020 Nov-Dec;33(6):885-893. doi: 10.3122/jabfm.2020.06.190461.
    • The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach.
    • Mogaka JJO, Chimbari MJ.
    • PLoS One. 2020 Oct 14;15(10):e0240585. doi: 10.1371/journal.pone.0240585.
    • Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    • Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, Hassen D, Snyder SR, Graves JA, Peterson JF, Williams MS, Veenstra DL.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2022874. doi: 10.1001/jamanetworkopen.2020.22874.

    Press: Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective. (Clinical OMICs)

    • NCCN Updates Guidelines Advising Against Using Polygenic Risk Scores Outside of Clinical Trials.
    • [No author given]
    • GenomeWeb. Diagnostics. 2020 Sep 10.
    • Genetic Testing Challenges in Oncology: Unnecessary Testing Identifies BRCA2 VUS in 16-Year-Old Girl.
    • Ray T.
    • Precision Oncology News. 2020 Sep 9.
    • Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial.
    • Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK.
    • Cancers (Basel). 2020 Sep 5;12(9):2526. doi: 10.3390/cancers12092526.
    • Parent of Origin Effects on Family Communication of Risk in BRCA+ Women: A Qualitative Investigation of Human Factors in Cascade Screening.
    • Dwyer AA, Hesse-Biber S, Flynn B, Remick S.
    • Cancers (Basel). 2020 Aug 17;12(8):2316. doi: 10.3390/cancers12082316.
    • The management of BRCA1 and BRCA2 carriers in Singapore.
    • Chiang J, Ngeow J.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-104. doi: 10.21037/cco-20-104. Epub ahead of print.
    • When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    • Antonarakis ES, Gomella LG, Petrylak DP.
    • Eur Urol Oncol. 2020 Aug 17:S2588-9311(20)30096-1. doi: 10.1016/j.euo.2020.07.005. Epub ahead of print.
    • From Probands to Relatives: Communication of Genetic Risk for Hereditary Breast-Ovarian Cancer and Its Influence on Subsequent Testing.
    • Seven M, Shah LL, Yazici H, Daack-Hirsch S.
    • Cancer Nurs. 2020 Aug 13. doi: 10.1097/NCC.0000000000000876. Epub ahead of print.
    • Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection.
    • Paradiso AV, Patruno M, Digennaro M, Tommasi S, Pilato B, Argentiero A, Brunetti O, Silvestris N.
    • Front Oncol. 2020 Aug 12;10:1292. doi: 10.3389/fonc.2020.01292.
    • Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
    • Jeong GW, Shin W, Lee DO, Seo SS, Kang S, Park SY, Lim MC.
    • Cancer Res Treat. 2020 Aug 11. doi: 10.4143/crt.2020.364. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Assuming All Labs Are Equal Gives False Reassurance of Risk.
    • Ray T.
    • Precision Oncology News. 2020 Aug 6.
    • BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.
    • Marchetti C, Minucci A, Pietragalla A, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001670. doi: 10.1136/ijgc-2020-001670. Epub ahead of print.

    Guidelines:

    Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.

    • Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    • Garcia C, Sullivan MW, Lothamer H, Harrison KM, Chatfield L, Thomas MH, Modesitt SC.
    • J Obstet Gynaecol Res. 2020 Jul 12. doi: 10.1111/jog.14366. Epub ahead of print.
    • Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    • Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, Mitchell CL, Badea D, Moon S, Hogg M, Hadjiyiannakis D, Clancy T, Schlecht H, Woodward ER, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Lalloo FI, Harkness EF, Evans DGR.
    • Eur J Hum Genet. 2020 Jul 10. doi: 10.1038/s41431-020-0692-y. Epub ahead of print.
    • Small Steps in Pancreatic Cancer – Episode 2: Relatives at Risk.
    • McAllister F, Maitra A, Burton M, McGuire M..
    • Medscape. 2020 Jun 25.
    • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    • Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG.
    • J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046. Epub ahead of print.

    Press: Cancer Experts Develop Precision Medicine-Based Genetic Testing Framework for Prostate Cancer. (GenomeWeb)

    Press: Consider Genetic Testing in All Metastatic Prostate Cancers. (MedPage Today)

    • Utilization of health information technology among cancer genetic counselors.
    • Ritchie JB, Allen CG, Morrison H, Nichols M, Lauzon SD, Schiffman JD, Hughes Halbert C, Welch BM.
    • Mol Genet Genomic Med. 2020 May 28:e1315. doi: 10.1002/mgg3.1315. Epub ahead of print.
    • AGA Clinical Practice Update on Pancreas Cancer Screening in High Risk Individuals: Expert Review.
    • Aslanian HR, Lee JH, Canto MI.
    • Gastroenterology. 2020 May 13:S0016-5085(20)30657-0. doi: 10.1053/j.gastro.2020.03.088. Epub ahead of print.
    • Review, Practice Guideline
    • The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure.
    • Menko FH, Jeanson KN, Bleiker EMA, van Tiggelen CWM, Hogervorst FBL, Ter Stege JA, Ait Moha D, van der Kolk LE.
    • Eur J Hum Genet. 2020 Apr 16. doi: 10.1038/s41431-020-0618-8. [Epub ahead of print]
    • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
    • Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, Lu KH, Sparacio D, Annunziata CM.
    • J Clin Oncol. 2020 Apr 10;38(11):1222-1245. doi: 10.1200/JCO.19.02960. Epub 2020 Jan 27.

    Commentary:

    BRCA status assessment in epithelial ovarian cancer and the challenge of tumor testing.

    • Genetic Testing Challenges in Oncology: Patient With BRCA1 VUS Has Prophylactic Surgery.
    • Ray T.
    • Precision Oncology News. 2020 Apr 6.
    • Analisi di minimizzazione dei costi di una strategia di test preventivo per le familiari di pazienti con carcinoma dell’ovaio BRCA mutato [A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer].
    • Brino ED, Ruggeri M, Boccia S, Cerana N, Lorusso D, Sacchini D, Savarese A, Varesco L, Cicchetti A.
    • Glob Reg Health Technol Assess. 2020 Apr 4;7:1-8. Italian. doi: 10.33393/grhta.2020.557.
    • Assessing relatives' readiness for hereditary cancer cascade genetic testing.
    • Bednar EM, Sun CC, McCurdy S, Vernon SW.
    • Genet Med. 2020 Apr;22(4):719-726. doi: 10.1038/s41436-019-0735-3. Epub 2019 Dec 20.

    Letter:

    Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.

    • Ethical Issues in Genetic Testing for Inherited Cancer Predisposition Syndromes: the Potentially Conflicting Interests of Patients and Their Relatives.
    • Kenny J, Burcher S, Kohut K, Eastman N.
    • Curr Genet Med Rep. 2020 Mar 17. doi: 10.1007/s40142-020-00186-8. [Epub ahead of print]
    • Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention.
    • Kassem N, Stout LA, Hunter C, Schneider B, Radovich M.
    • JCO Precis Oncol. 2020;4:96. doi: 10.1200/PO.19.00278. Epub 2020 Feb 26.
    • Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    • Weidner AE, Liggin ME, Zuniga BI, Tezak AL, Wiesner GL, Pal T.
    • Cancer. 2020 Jan 22. doi: 10.1002/cncr.32715. [Epub ahead of print]
    • Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.
    • Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires , Christos P, Anderson S, Mukherjee S, Jordan B, Blank , Caputo TA, Sharaf , Offit K, Holcomb K, Lipkin S.
    • J Clin Oncol. 2020 Jan 10:JCO1902005. doi: 10.1200/JCO.19.02005. [Epub ahead of print]
    • Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.
    • Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, Lipkin SM, Robson ME, Hamilton JG, Vijai J, Mukherjee S.
    • J Clin Oncol. 2020 Jan 10:JCO1902010. doi: 10.1200/JCO.19.02010. [Epub ahead of print]
    • Exploring relatives' perceptions of participation, ethics, and communication in a patient-driven study for hereditary cancer variant reclassification.
    • Tsai GJ, Chen AT, Garrett LT, Burke W, Bowen DJ, Shirts BH.
    • J Genet Couns. 2020 Jan 9. doi: 10.1002/jgc4.1215. [Epub ahead of print]
    • Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793.
    • [No authors listed]
    • Obstet Gynecol. 2019 Dec;134(6):e143-e149. doi: 10.1097/AOG.0000000000003562.

    Summary:

    Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793.

    • Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
    • Griffin NE, Buchanan TR, Smith SH, Leon AA, Meyer MF, Liu J, Tabak RG, Fuh KC, Thaker PH, Powell MA, Mutch DG, Massad LS, Colditz GA, Hagemann AR.
    • Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31626-9. doi: 10.1016/j.ygyno.2019.11.005. [Epub ahead of print]
    • BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling.
    • Chao A, Lin YH, Yang LY, Wu RC, Chang WY, Chang PY, Chang SC, Lin CY, Huang HJ, Lin CT, Chou HH, Huang KG, Kuo WL, Chang TC, Lai CH.
    • J Gynecol Oncol. 2019 Oct 25. doi: 10.3802/jgo.2020.31.e24. [Epub ahead of print]
    • Calling on Primary Care to Prevent BRCA-Related Cancers.
    • Armstrong K.
    • J Gen Intern Med. 2019 Oct 21. doi: 10.1007/s11606-019-05469-7. [Epub ahead of print]
    • How to inform relatives at risk of hereditary diseases? A mixed-methods systematic review on patient attitudes.
    • van den Heuvel LM, Smets EMA, van Tintelen JP, Christiaans I.
    • J Genet Couns. 2019 Oct;28(5):1042-1058. doi: 10.1002/jgc4.1143. Epub 2019 Jun 19.
    • Review
    • Familial disclosure by genetic healthcare professionals: a useful but sparingly used legal provision in France.
    • Derbez B, de Pauw A, Stoppa-Lyonnet D, Galactéros F, de Montgolfier S.
    • J Med Ethics. 2019 Aug 28. pii: medethics-2018-105212. doi: 10.1136/medethics-2018-105212. [Epub ahead of print]
    • The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.
    • Peshkin BN, Ladd MK, Isaacs C, Segal H, Jacobs A, Taylor KL, Graves KD, O'Neill SC, Schwartz MD.
    • J Cancer Educ. 2019 Aug 11. doi: 10.1007/s13187-019-01599-y. [Epub ahead of print]
    • Uptake of genetic counseling among adult children of BRCA1/2 mutation carriers in France.
    • Gauna Cristaldo FB, Touzani R, Apostolidis T, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Fricker JP, Berthet P, Julian-Reynier C, Mancini J, Noguès C, Bouhnik AD.
    • Psychooncology. 2019 Jul 5. doi: 10.1002/pon.5169. [Epub ahead of print]
    • Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men.
    • Chandrasekar T, Gross L, Gomella LG, Hegarty SE, Leong JY, Giri VN.
    • Eur Urol Oncol. 2019 Jul 2. pii: S2588-9311(19)30085-9. doi: 10.1016/j.euo.2019.06.010. [Epub ahead of print]
    • [Hereditary Breast and Ovarian Cancer Syndrome].
    • Inuzuka M, Nakamura S.
    • Gan To Kagaku Ryoho. 2019 Jul;46(7):1109-1113.
    • Review, [Article in Japanese]
    • Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among 103 French families with BRCA1/2 or MMR gene mutations.
    • Alegre N, Vande Perre P, Bignon YJ, Michel A, Galibert V, Mophawe O, Corsini C, Coupier I, Chiesa J, Robert L, Bernhard L, Picot MC, Bertet H, Macioce V, Bastide N, Solassol J, Rey JM, Thomas F, Carton S, Pujol P.
    • Psychooncology. 2019 Jun 1. doi: 10.1002/pon.5142. [Epub ahead of print]
    • [Risks of Solid Tumors in Heterozygous Carriers of Recessive Syndromes.]
    • Koudová M, Puchmajerová A.
    • Klin Onkol. 2019 Summer;32(Supplementum2):14-23. doi: 10.14735/amko2019S14.
    • Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk.
    • Young AL, Butow PN, Rhodes P, Tucker KM, Williams R, Healey E, Wakefield CE.
    • J Genet Couns. 2019 Jun;28(3):516-532. doi: 10.1002/jgc4.1055. Epub 2019 Jan 29.
    • Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?
    • Thomas MH, Higgs LK, Modesitt SC, Schroen AT, Ring KL, Dillon PM.
    • J Genet Couns. 2019 Jun;28(3):700-707. doi: 10.1002/jgc4.1044. Epub 2019 Feb 1.
    • Case report
    • Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    • Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.
    • Crit Rev Oncol Hematol. 2019 May 25;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. [Epub ahead of print]
    • Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
    • Moss CA, Cojocaru E, Hanwell J, Ward S, Xu W, van Zyl M, O'Leary L, de Bono JS, Banerji U, Kaye SB, Minchom A, George AJ, Lopez J, McVeigh TP.
    • Eur J Cancer. 2019 May 9;114:97-106. doi: 10.1016/j.ejca.2019.04.009. [Epub ahead of print]
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
    • Zakrzewski F, Gieldon L, Rump A, Seifert M, Grützmann K, Krüger A, Loos S, Zeugner S, Hackmann K, Porrmann J, Wagner J, Kast K, Wimberger P, Baretton G, Schröck E, Aust D, Klink B.
    • BMC Cancer. 2019 Apr 27;19(1):396. doi: 10.1186/s12885-019-5584-6.
    • Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma.
    • Peters MLB, Stobie L, Dudley B, Karloski E, Allen K, Speare V, Dolinsky JS, Tian Y, DeLeonardis K, Krejdovsky J, Button A, Lim C, Borazanci E, Brand R, Tung N.
    • Cancer. 2019 Apr 12. doi: 10.1002/cncr.32077. [Epub ahead of print]
    • Germline Genetic Testing: What the Breast Surgeon Needs to Know.
    • Plichta JK, Sebastian ML, Smith LA, Menendez CS, Johnson AT, Bays SM, Euhus DM, Clifford EJ, Jalali M, Kurtzman SH, Taylor WA, Hughes KS.
    • Ann Surg Oncol. 2019 Apr 2. doi: 10.1245/s10434-019-07341-8. [Epub ahead of print]
    • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    • Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.
    • Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
    • Electronically ascertained extended pedigrees in breast cancer genetic counseling.
    • Stefansdottir V, Skirton H, Johannsson OT, Olafsdottir H, Olafsdottir GH, Tryggvadottir L, Jonsson JJ.
    • Fam Cancer. 2019 Apr;18(2):153-160. doi: 10.1007/s10689-018-0105-3.
    • Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    • Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, Lee JEA, Lewis A, Morgan JA, Limb S, Young MA, James PA, Trainer AH, Campbell IG.
    • Genet Med. 2019 Apr;21(4):913-922. doi: 10.1038/s41436-018-0277-0. Epub 2018 Sep 26.
    • A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    • Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA.
    • Gynecol Oncol. 2019 Apr;153(1):100-107. doi: 10.1016/j.ygyno.2019.01.019. Epub 2019 Feb 1.
    • Disparities in gynecologic cancer genetics evaluation.
    • Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2019 Apr;153(1):184-191. doi: 10.1016/j.ygyno.2019.01.024. Epub 2019 Jan 31.
    • Review
    • Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    • Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J.
    • Curr Oncol Rep. 2019 Mar 27;21(5):42. doi: 10.1007/s11912-019-0790-6.
    • Review
    • Evaluation of the template letter regarding the disclosure of genetic information within the family in France.
    • Zordan C, Monteil L, Haquet E, Cordier C, Toussaint E, Roche P, Dorian V, Maillard A, Lhomme E, Richert L, Pasquier L, Akloul L, Taris N, Lacombe D.
    • J Community Genet. 2019 Mar 27. doi: 10.1007/s12687-019-00418-7. [Epub ahead of print]
    • "It would be so much easier": health system-led genetic risk notification-feasibility and acceptability of cascade screening in an integrated system.
    • Henrikson NB, Blasi PR, Fullerton SM, Grafton J, Leppig KA, Jarvik GP, Larson EB.
    • J Community Genet. 2019 Mar 6. doi: 10.1007/s12687-019-00412-z. [Epub ahead of print]
    • RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Peshkin BN, Isaacs C, Schwartz MD.
    • J Natl Cancer Inst. 2019 Mar 5. pii: djz028. doi: 10.1093/jnci/djz028. [Epub ahead of print]

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    Original research:

    Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    • BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    • Kwon JS, Tinker AV, Hanley GE, Pansegrau G, Sun S, Carey MS, Schrader I.
    • Gynecol Oncol. 2019 Mar;152(3):459-464. doi: 10.1016/j.ygyno.2018.10.014.
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    • Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.
    • Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.
    • Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
    • Connors LM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):32-35. doi: 10.1188/19.CJON.32-35.
    • Review
    • A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.
    • Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA.
    • Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):293-302. doi: 10.1158/1055-9965.EPI-18-0584. Epub 2019 Jan 28.
    • Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.
    • Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis PO, Kohler C, Erlanger TE, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse LL, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands EJG, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi MC; for the CASCADE Consortium.
    • Public Health Genomics. 2019 Jan 29:1-12. doi: 10.1159/000496495. [Epub ahead of print]
    • Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    • Hoskins P, Eccleston A, Hurry M, Dyer M.
    • Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061-7. doi: 10.1016/j.ygyno.2019.01.018. [Epub ahead of print]
    • Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW.
    • J Natl Cancer Inst. 2019 Jan 1;111(1):95-98. doi: 10.1093/jnci/djy147.

    Letter, comment:

    RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    • Menko FH, Ter Stege JA, van der Kolk LE, Jeanson KN, Schats W, Moha DA, Bleiker EMA.
    • Fam Cancer. 2019 Jan;18(1):127-135. doi: 10.1007/s10689-018-0089-z.
    • Review
    • Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation.
    • Ramos MCA, Folgueira MAAK, Maistro S, Campolina AG, Soárez PC, Bock GH, Novaes HMD, Diz MDPE.
    • Rev Saude Publica. 2018 Nov 29;52:94. doi: 10.11606/S1518-8787.2018052000643.
    • Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
    • Hall ET, Parikh D, Caswell-Jin JL, Gupta T, Mills MA, Kingham KE, Koff R, Ford JM, Kurian AW.
    • JCO Precis Oncol. [2018 Nov 8];2:1-10. doi: 10.1200/PO.18.00167.
    • Familial communication and cascade testing among relatives of BRCA population screening participants.
    • Lieberman S, Lahad A, Tomer A, Koka S, BenUziyahu M, Raz A, Levy-Lahad E.
    • Genet Med. 2018 Nov;20(11):1446-1454. doi: 10.1038/gim.2018.26. Epub 2018 Mar 29.
    • Germline and somatic genetic testing in ovarian cancer patients.
    • Chandrasekaran D, Manchanda R.
    • BJOG. 2018 Oct;125(11):1460. doi: 10.1111/1471-0528.15225. Epub 2018 May 10.
    • Commentary
    • Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
    • Tuffaha HW, Mitchell A, Ward RL, Connelly L, Butler JRG, Norris S, Scuffham PA.
    • Genet Med. 2018 Sep;20(9):985-994. doi: 10.1038/gim.2017.231. Epub 2018 Jan 4.
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.
    • Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, Gan C, Taylor R, Turnbull C, Legood R, Zaikin A, Antoniou AC, Menon U, Jacobs I.
    • J Med Genet. 2018 Aug;55(8):538-545. doi: 10.1136/jmedgenet-2017-105195. Epub 2018 Apr 5.
    • The resounding effect of DNA repair deficiency in prostate cancer.
    • Cheng HH.
    • Urol Oncol. 2018 Aug;36(8):385-388. doi: 10.1016/j.urolonc.2018.02.014. Epub 2018 Mar 17.
    • Review
    • Development of a Web-based Family Intervention for BRCA Carriers and Their Biological Relatives: Acceptability, Feasibility, and Usability Study.
    • Katapodi MC, Jung M, Schafenacker AM, Milliron KJ, Mendelsohn-Victor KE, Merajver SD, Northouse LL.
    • JMIR Cancer. 2018 Apr 13;4(1):e7. doi: 10.2196/cancer.9210.
    • A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G.
    • BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
    • Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study.
    • Eng KH, Szender JB, Etter JL, Kaur J, Poblete S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, Krolewski JJ, Zsiros E, Frederick PJ, Lele SB, Moysich KB, Odunsi KO.
    • PLoS Genet. 2018 Feb 15;14(2):e1007194. doi: 10.1371/journal.pgen.1007194. eCollection 2018 Feb.
    • Genetic Testing: Multiple Problems to Solve.
    • Ramos E, Haidle JL.
    • J Clin Oncol. 2018 Feb 10;36(5):518-519. doi: 10.1200/JCO.2017.76.0942. Epub 2018 Jan 2.

    Editorial:

    Genetic Testing: What Problem Are We Trying to Solve?

    Letter, Reply:

    Reply to E. Ramos et al.

    • Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
    • Moss HA, Samimi G, Havrilesky LJ, Sherman ME, Myers ER.
    • Genet Epidemiol. 2018 Feb;42(1):117-122. doi: 10.1002/gepi.22095. Epub 2017 Nov 30.
    • Genetic variants of prospectively demonstrated phenocopies in BRCA1/2 kindreds.
    • Dominguez-Valentin M, Evans DGR, Nakken S, Tubeuf H, Vodak D, Ekstrøm PO, Nissen AM, Morak M, Holinski-Feder E, Martins A, Møller P, Hovig E.
    • Hered Cancer Clin Pract. 2018 Jan 15;16:4. doi: 10.1186/s13053-018-0086-0. eCollection 2018.
    • Improving attendance to genetic counselling services for gynaecological oncology patients.
    • Pokharel HP, Hacker NF, Andrews L.
    • Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018.
    • ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer.
    • [No authors listed]
    • Obstet Gynecol. 2018 Jan;131(1):e31-e34. doi: 10.1097/AOG.0000000000002457.

    Summary:

    ACOG Committee Opinion No. 727 Summary: Cascade Testing: Testing Women For Known Hereditary Genetic Mutations Associated With Cancer.

    Press: 'Cascade Testing' Important for Hereditary Gynecologic Cancers: ACOG (Medscape/Reuters)

    • Using family history forms in pediatric oncology to identify patients for genetic assessment.
    • Hamilton A, Smith E, Hamon J, Tomiak E, Bassal M, Sawyer SL.
    • Curr Oncol. 2017 Dec;24(6):e441-e445. doi: 10.3747/co.24.3710. Epub 2017 Dec 20.
    • Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care.
    • Walsh MF, Kennedy J, Harlan M, Kentsis A, Shukla N, Musinsky J, Roberts S, Kung AL, Robson M, Kushner BH, Meyers P, Offit K.
    • Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a001925. doi: 10.1101/mcs.a001925. Print 2017 Nov.
    • Traceback: leveraging archived biospecimens to identify mutation carriers.
    • Samimi G, Sherman ME.
    • Oncotarget. 2017 Oct 11;8(53):90628-90629. doi: 10.18632/oncotarget.21742. eCollection 2017 Oct 31.
    • Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
    • Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R5, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO.
    • JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.
    • Barriers and Facilitating Factors for Implementation of Genetic Services: A Public Health Perspective.
    • Cornel MC, van El CG.
    • Front Public Health. 2017 Aug 4;5:195. doi: 10.3389/fpubh.2017.00195. eCollection 2017.
    • Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper.
    • Randall LM, Pothuri B, Swisher EM, Diaz JP, Buchanan A, Witkop CT, Bethan Powell C, Smith EB, Robson ME, Boyd J, Coleman RL, Lu K.
    • Gynecol Oncol. 2017 Aug;146(2):217-224. doi: 10.1016/j.ygyno.2017.06.002. Epub 2017 Jun 7.
    • Identification of BRCA1 and BRCA2 Mutation Carriers Through a Traceback Framework: Consent, Privacy, and Autonomy.
    • Schwartz MD.
    • J Clin Oncol. 2017 Jul 10;35(20):2226-2228. doi: 10.1200/JCO.2017.72.8774. Epub 2017 May 2.

    Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

    • Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
    • Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.
    • J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.

    Editorial:

    Identification of BRCA1 and BRCA2 Mutation Carriers Through a Traceback Framework: Consent, Privacy, and Autonomy.

    • Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    • Crawford B, Adams SB, Sittler T, van den Akker J, Chan S, Leitner O, Ryan L, Gil E, van 't Veer L.
    • Breast Cancer Res Treat. 2017 Jun;163(2):383-390. doi: 10.1007/s10549-017-4181-0. Epub 2017 Mar 9.
    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    • Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.
    • Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.
    • Recruiting families at risk for hereditary breast and ovarian cancer from a statewide cancer registry: a methodological study.
    • Katapodi MC, Duquette D, Yang JJ, Mendelsohn-Victor K, Anderson B, Nikolaidis C, Mancewicz E, Northouse LL, Duffy S, Ronis D, Milliron KJ, Probst-Herbst N, Merajver SD, Janz NK, Copeland G, Roberts S.
    • Cancer Causes Control. 2017 Mar;28(3):191-201. doi: 10.1007/s10552-017-0858-2. Epub 2017 Feb 14.
    • Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
    • Darooei M, Poornima S, Salma BU, Iyer GR, Pujar AN, Annapurna S, Shah A, Maddali S, Hasan Q.
    • Tumour Biol. 2017 Feb;39(2):1010428317694303. doi: 10.1177/1010428317694303.
    • Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
    • D'Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, Villari P.
    • Genet Med. 2016 Dec;18(12):1171-1180. doi: 10.1038/gim.2016.29. Epub 2016 Apr 14.
    • The psychological impact of genetic information on children: a systematic review.
    • Wakefield CE, Hanlon LV, Tucker KM, Patenaude AF, Signorelli C, McLoone JK, Cohn RJ.
    • Genet Med. 2016 Aug;18(8):755-62. doi: 10.1038/gim.2015.181. Epub 2016 Jan 7.

    Commentary:

    Predictive genetic testing of minors: evidence and experience with families.

    • A cost analysis of a cancer genetic service model in the UK.
    • Slade I, Hanson H, George A, Kohut K, Strydom A, Wordsworth S, Rahman N; MCG programme.
    • J Community Genet. 2016 Jul;7(3):185-94. doi: 10.1007/s12687-016-0266-4. Epub 2016 Feb 27.
    • Discussion: Should We Test Minors For Hereditary Cancer Syndromes?
    • [No author given]
    • My Gene Counsel. 2016 May 2.
    • Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations.
    • Elvira D’Andrea, Carolina Marzuillo, Corrado De Vito, Marco Di Marco, Erica Pitini, Maria Rosaria Vacchio, Paolo Villari.
    • Genet Med. 2016 Apr 14.
    • The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety.
    • Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, De Grève J.
    • Fam Cancer. 2016 Apr;15(2):155-62. doi: 10.1007/s10689-015-9854-4.
    • Cost-Effectiveness Analysis of Testing for Brca1 and Brca2 Mutations In Women Diagnosed With Ovarian Cancer and Their Female First- And Second Degree Relatives Using A Discrete Event Simulation: A Uk Health Service Perspective.
    • Eccleston A, Bentley A, Dyer M, Vereecken W, George A, Rahman .
    • Value Health. 2015 Nov;18(7):A361. doi: 10.1016/j.jval.2015.09.697. Epub 2015 Oct 20.
    • Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
    • Trottier M, Lunn J, Butler R, Curling D, Turnquest T, Royer R, Akbari MR, Donenberg T, Hurley J, Narod SA.
    • Clin Genet. 2015 Aug;88(2):182-6. doi: 10.1111/cge.12468. Epub 2014 Sep 6.
    • Testing helps fight ovarian, breast cancers—but not everyone agrees on how to do it.
    • Maria Delaney.
    • Ars Technica. 2015 Jul 1.
    • How Genetic Tests Can Reveal a Hidden Family History of Cancer.
    • [No author given]
    • NBC Nightly News. 2015 May 20.
    • Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
    • Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA.
    • J Clin Oncol. 2015 Feb 1;33(4):304-11. doi: 10.1200/JCO.2014.57.1414. Epub 2014 Dec 1.

    Evolution of genetic testing for inherited susceptibility to breast cancer.

    • A primary care audit of familial risk in patients with a personal history of breast cancer.
    • Nathan P, Ahluwalia A, Chorley W.
    • Fam Cancer. 2014 Dec;13(4):591-4. doi: 10.1007/s10689-014-9737-0.
    • Linking distant relatives with BRCA gene mutations: potential for cost savings.
    • Senter L, O'Connor M, Oriyo F, Sweet K, Toland A.
    • Clin Genet. 2014 Jan;85(1):54-8. doi: 10.1111/cge.12211. Epub 2013 Jun 24.
    • Family Communication of BRCA1/2 Results and Family Uptake of BRCA1/2 Testing in a Diverse Population of BRCA1/2 Carriers.
    • Fehniger J, Lin F, Beattie MS, Joseph G, Kaplan C.
    • J Genet Couns. 2013 Oct;22(5):603-12. doi: 10.1007/s10897-013-9592-4. Epub 2013 May 12.
    • Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    • Pujol P, Lyonnet DS, Frebourg T, Blin J, Picot MC, Lasset C, Dugast C, Berthet P, de Paillerets BB, Sobol H, Grandjouan S, Soubrier F, Buecher B, Guimbaud R, Lidereau R, Jonveaux P, Houdayer C, Giraud S, Olschwang S, Nogue E, Galibert V, Bara C, Nowak F, Khayat D, Nogues C.
    • Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.
    • Significant Under-Use of Genetic Testing for Inherited Cancers Puts Health of Entire Families at Risk.
    • [No author given].
    • ScienceDaily. 2013 Jun 7.
    • Using a state cancer registry to recruit young breast cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versus a tailored intervention to increase breast cancer screening.
    • Katapodi MC, Northouse LL, Schafenacker AM, Duquette D, Duffy SA, Ronis DL, Anderson B, Janz NK, McLosky J, Milliron KJ, Merajver SD, Duong LM, Copeland G.
    • BMC Cancer. 2013 Mar 1;13:97. doi: 10.1186/1471-2407-13-97.
    • Proposed roadmap to stepwise integration of genetics in family medicine and clinical research.
    • Houwink EJ, Sollie AW, Numans ME, Cornel MC.
    • Clin Transl Med. 2013 Feb 16;2(1):5. doi: 10.1186/2001-1326-2-5.
    • BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families.
    • Fischer C, Engel C, Sutter C, Zachariae S, Schmutzler R, Meindl A, Heidemann S, Grimm T, Goecke TO, Debatin I, Horn D, Wieacker P, Gadzicki D, Becker K, Schäfer D, Stock F, Voigtländer T; German Consortium for Hereditary Breast and Ovarian Cancer.
    • Clin Genet. 2012 Nov;82(5):478-83. doi: 10.1111/j.1399-0004.2011.01788.x. Epub 2011 Oct 19.
    • A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer.
    • Engel NJ, Gordon P, Thull DL, Dudley B, Herstine J, Jankowitz RC, Zorn KK.
    • Fam Cancer. 2012 Sep;11(3):419-27. doi: 10.1007/s10689-012-9530-x.
    • Grace Rock's consent.
    • Ross TS.
    • Endocr Relat Cancer. 2012 Jul 22;19(4):C29-31. doi: 10.1530/ERC-12-0186. Print 2012 Aug.